Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease - PubMed (original) (raw)
Review
Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease
D T Kobayashi et al. Genes Brain Behav. 2005 Apr.
Free article
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative affliction of the elderly, presenting with progressive memory loss and dementia and terminating with death. There have been significant advances in understanding the biology and subsequent diagnosis of AD; however, the furious pace of research has not yet translated into a disease-modifying treatment. While scientific inquiry in AD is largely centered on identifying biological players and pathological mechanisms, the day-to-day realities of AD patients and their caregivers revolve around their steady and heartbreaking cognitive decline. In the past decade, AD research has been fundamentally transformed by the development of genetically modified animal models of amyloid-driven neurodegeneration. These important in vivo models not only replicate some of the hallmark pathology of the disease, such as plaque-like amyloid accumulations and astrocytic inflammation, but also some of the cognitive impairments relevant to AD. In this article, we will provide a detailed review of the behavioral and cognitive deficits present in several transgenic mouse models of AD and discuss their functional changes in response to experimental treatments.
Similar articles
- Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF. Ohno M, et al. Eur J Neurosci. 2006 Jan;23(1):251-60. doi: 10.1111/j.1460-9568.2005.04551.x. Eur J Neurosci. 2006. PMID: 16420434 - Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Melnikova T, Savonenko A, Wang Q, Liang X, Hand T, Wu L, Kaufmann WE, Vehmas A, Andreasson KI. Melnikova T, et al. Neuroscience. 2006 Sep 1;141(3):1149-62. doi: 10.1016/j.neuroscience.2006.05.001. Epub 2006 Jun 6. Neuroscience. 2006. PMID: 16753269 - Transgenic mouse models of Alzheimer's disease: phenotype and application.
Higgins GA, Jacobsen H. Higgins GA, et al. Behav Pharmacol. 2003 Sep;14(5-6):419-38. doi: 10.1097/01.fbp.0000088420.18414.ff. Behav Pharmacol. 2003. PMID: 14501255 Review. - Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse.
Chen Q, Nakajima A, Choi SH, Xiong X, Tang YP. Chen Q, et al. J Neurosci Res. 2008 May 15;86(7):1615-25. doi: 10.1002/jnr.21601. J Neurosci Res. 2008. PMID: 18189321 - A decade of modeling Alzheimer's disease in transgenic mice.
McGowan E, Eriksen J, Hutton M. McGowan E, et al. Trends Genet. 2006 May;22(5):281-9. doi: 10.1016/j.tig.2006.03.007. Epub 2006 Mar 29. Trends Genet. 2006. PMID: 16567017 Review.
Cited by
- Cannabinoid type-1 receptor signaling in dopaminergic Engrailed-1 expressing neurons modulates motivation and depressive-like behavior.
Baddenhausen S, Lutz B, Hofmann C. Baddenhausen S, et al. Front Mol Neurosci. 2024 Apr 4;17:1379889. doi: 10.3389/fnmol.2024.1379889. eCollection 2024. Front Mol Neurosci. 2024. PMID: 38660383 Free PMC article. - Updates on mouse models of Alzheimer's disease.
Zhong MZ, Peng T, Duarte ML, Wang M, Cai D. Zhong MZ, et al. Mol Neurodegener. 2024 Mar 11;19(1):23. doi: 10.1186/s13024-024-00712-0. Mol Neurodegener. 2024. PMID: 38462606 Free PMC article. Review. - Sex- and region-specific cortical and hippocampal whole genome transcriptome profiles from control and APP/PS1 Alzheimer's disease mice.
Papazoglou A, Henseler C, Weickhardt S, Teipelke J, Papazoglou P, Daubner J, Schiffer T, Krings D, Broich K, Hescheler J, Sachinidis A, Ehninger D, Scholl C, Haenisch B, Weiergräber M. Papazoglou A, et al. PLoS One. 2024 Feb 7;19(2):e0296959. doi: 10.1371/journal.pone.0296959. eCollection 2024. PLoS One. 2024. PMID: 38324617 Free PMC article. - 14-3-3θ Does Not Protect against Behavioral or Pathological Deficits in Alzheimer's Disease Mouse Models.
Gannon M, Wang B, Stringfellow SA, Quintin S, Mendoza I, Srikantha T, Roberts AC, Saito T, Saido TC, Roberson ED, Yacoubian TA. Gannon M, et al. eNeuro. 2022 Jun 24;9(3):ENEURO.0368-21.2022. doi: 10.1523/ENEURO.0368-21.2022. Print 2022 May-Jun. eNeuro. 2022. PMID: 35697511 Free PMC article. - Neuronal ROS-induced glial lipid droplet formation is altered by loss of Alzheimer's disease-associated genes.
Moulton MJ, Barish S, Ralhan I, Chang J, Goodman LD, Harland JG, Marcogliese PC, Johansson JO, Ioannou MS, Bellen HJ. Moulton MJ, et al. Proc Natl Acad Sci U S A. 2021 Dec 28;118(52):e2112095118. doi: 10.1073/pnas.2112095118. Proc Natl Acad Sci U S A. 2021. PMID: 34949639 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous